1.85
+0(+0.00%)
Currency In USD
| Previous Close | 1.85 |
| Open | 1.82 |
| Day High | 1.94 |
| Day Low | 1.8 |
| 52-Week High | 4.32 |
| 52-Week Low | 1.19 |
| Volume | 5.92M |
| Average Volume | 4.32M |
| Market Cap | 379.14M |
| PE | 2.94 |
| EPS | 0.63 |
| Moving Average 50 Days | 2.12 |
| Moving Average 200 Days | 2.43 |
| Change | 0 |
If you invested $1000 in Taysha Gene Therapies, Inc. (TSHA) since IPO date, it would be worth $76.89 as of December 22, 2024 at a share price of $1.85. Whereas If you bought $1000 worth of Taysha Gene Therapies, Inc. (TSHA) shares 3 years ago, it would be worth $140.47 as of December 22, 2024 at a share price of $1.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
GlobeNewswire Inc.
Nov 06, 2024 1:00 PM GMT
DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 04, 2024 12:01 PM GMT
DALLAS, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous
Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress
GlobeNewswire Inc.
Sep 26, 2024 12:00 PM GMT
DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseas